PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
A. R. Mato,
W. G. Wierda,
J. M. Pagel,
M. S. Davids,
P. L. Zinzani,
Y. Lu,
H. Liu,
S. Shahda,
C. C. Leow,
C. S. Tam,
J. A. Woyach,
T. A. Eyre
Affiliations
A. R. Mato
1 Memorial Sloan Kettering Cancer Center, New York
W. G. Wierda
2 University of Texas MD Anderson Cancer Center, Houston
J. M. Pagel
3 Loxo Oncology at Lilly, Stamford
M. S. Davids
4 Dana-Farber Cancer Institute, Harvard Medical School, Boston, United States of America
P. L. Zinzani
5 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy
Y. Lu
6 Elli Lily and Company, Indianapolis, United States of America
H. Liu
3 Loxo Oncology at Lilly, Stamford
S. Shahda
3 Loxo Oncology at Lilly, Stamford
C. C. Leow
3 Loxo Oncology at Lilly, Stamford
C. S. Tam
7 Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia
J. A. Woyach
8 The Ohio State University Comprehensive Cancer Center, Columbus, United States of America
T. A. Eyre
9 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom
